Drug Database
DE

delivery technology (CEFORM EA / CEFORM RA / CEFORM)

✓ Approved

Bausch Health Companies Inc. · therapeutic agent

What is delivery technology?

delivery technology is a therapeutic agent developed by Bausch Health Companies Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCEFORM EA, CEFORM RA, CEFORM
CompanyBausch Health Companies Inc.
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Bausch Health Companies Inc.

Therapeutic Indications

delivery technology is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedInternational journal of pharmaceutics: X2026-08-30

Optimizing nucleic acid delivery using PF14 peptide and lipid nanoparticle systems.

Daniele Delia D, Hein Zaw Myo ZM, Saher Osama O, El-Serafi Ibrahim I

Nucleic acid-based therapeutics are a rapidly expanding class of precision medicines capable of directly modulating gene expression. However, their clinical application is limited by challenges in cellular delivery, including large molecular size, hydrophilicity, and susceptibility to enzymatic degradation. To address these barriers, advanced delivery platforms such as cell-penetrating peptides and lipid nanoparticles (LNPs) have been developed. This study evaluates two delivery systems: the cell-penetrating peptide PepFect-14 (PF14) and LNP formulations, for enhancing nucleic acid delivery and cellular uptake. PF14 facilitates intracellular transport through peptide-nucleic acid complex formation, while LNPs protect cargo from degradation and can promote endosomal escape. Their performance was assessed under different conditions using luciferase-based reporter systems in HeLa cells. PF14-mediated delivery of the splice-switching oligonucleotide ON-705 in HeLa 705 cells showed efficient splice correction, with activity increasing in a dose- and molar ratio- dependent manner, reaching a plateau at a 1:10 ratio. Delivery efficiency was significantly influenced by formulation conditions, with Opti-MEM outperforming standard media and sugar-based buffers. Polymer excipients also affected activity as PVA18, PVA40, and PVP40 enhanced performance, while low molecular weight PVP reduced efficacy. In parallel, LNP-mediated delivery of luciferase mRNA in wild-type HeLa cells demonstrated robust, dose-dependent protein expression. Both systems maintained high cell viability (80-100%). Overall, these findings highlight the importance of formulation optimization in improving nucleic acid delivery and provide practical insights for enhancing peptide- and lipid-based therapeutic platforms.

PMID 42668503
Read full article →
PubMedMaterials today. Bio2026-08-30

Targeted delivery of peptidoglycan hydrolases (PGH) via engineered extracellular vesicles (EVs) to clear intracellular bacterial infections.

Sabani Besmira B, Leone Martina M, Gasser Lynn L, Sumrall Eric E et al.

Bacterial infectious diseases remain a major global health threat due to increasing antibiotic resistance. Further complicating effective treatment, some pathogens such as Staphylococcus aureus persist within host cells. Peptidoglycan hydrolases (PGHs), including bacteriophage-derived endolysins, represent a promising class of novel antimicrobials due to their rapid bacteriolytic activity and low risk of resistance emergence. However, their clinical application is limited by an unfavourable PK profile and inefficient delivery into infected host cells. Here, we engineered extracellular vesicles (EVs) for the targeted, intracellular delivery of GH15, a novel endolysin against S. aureus. GH15-loaded EVs, functionalized with antibodies targeting αvβ3 integrin on bacterially infected cells, efficiently delivered GH15 into S. aureus-positive endothelial cells and macrophages in vitro and eliminated intracellular bacteria. In addition, GH15-loaded EVs promoted the clearance of intracellular bacteria in macrophages of infected zebrafish larvae in vivo. Our findings establish EVs as effective vehicles for intracellular delivery of antimicrobial enzymes and highlight their potential for the treatment of intracellular bacterial infections.

PMID 42668579
Read full article →
PubMedCureus2026-08-30

Effectiveness of Adherence to Antenatal Exercise on Labor Duration in Normal Vaginal Delivery.

Desai Sakshi S SS, S Anandh A

Prolonged labor during normal delivery is a common concern influenced by maternal factors such as age, fitness level, and pregnancy-related weight gain. Adherence to antenatal exercise programs, which often include breathing exercises, stretching, and pelvic floor components, is evidently related to enhanced labor outcomes. This study investigates the effectiveness of adherence to antenatal exercises in relation to the duration of labor in women planning to undergo normal delivery. The present study included 44 pregnant women in the third trimester (aged 20-30 years) planning normal vaginal delivery. Participants were randomly divided by sealed envelope method into Group A (control, n = 22) receiving conventional exercises and Group B (experimental, n = 22) receiving a structured antenatal exercise program including progressive yoga poses over 12 weeks. Outcome measures included the duration of labor, Numerical Pain Rating Scale (NPRS), and Borg Rating of Perceived Exertion (RPE) Scale. Following the 12-week intervention, women in the experimental group (Group B) demonstrated significantly shorter total labor duration (6.4 ± 1.2 hours) compared to the control group (Group A) (7.8 ± 1.4 hours, t = 3.56, p < 0.05). Group B also demonstrated significantly lower pain intensity on the NPRS (2.93 ± 0.73) compared to Group A (5.79 ± 1.36). Similarly, Group B reported significantly lower perceived exertion on the Borg RPE (7.5 ± 1.45) compared to Group A (12.5 ± 1.02). Within-group analysis confirmed that both groups showed significant improvement from pre- to post-intervention on the NPRS and Borg RPE Scale (labor duration, being a single delivery-time outcome, was not assessed pre-intervention), and the magnitude of improvement was markedly greater in Group B across all outcome measures. Mean session adherence was comparable between groups (91.3% in Group B vs. 88.6% in Group A, p = 0.32), indicating that the observed between-group differences were not attributable to differential compliance. The study suggests that among pregnant women planning to undergo normal delivery, structured antenatal exercises may be more effective than traditional exercises in decreasing duration of labor, pain, and physical exertion; given the modest sample size, these findings should be interpreted with caution and confirmed in larger trials.

PMID 42668864
Read full article →
PubMedBiomaterials2026-08-30

Polyphenol-engineered selenium nanocatalysts enable neuroprotective glioblastoma chemoimmunotherapy via nose-to-brain delivery.

Hong Shunming S, Hu Rong R, Nie Qingbin Q, Ruan Huaqiang H et al.

Glioblastoma therapy is severely limited by poor blood-brain barrier (BBB) penetration and systemic toxicity of chemotherapeutics. Here, we engineered polyphenol-stabilized selenium nanoparticles (nGPSe NPs, <60 nm) via spatial confinement synthesis as a redox-dual nanocatalytic carrier for afatinib (AFA). These AFA@nGPSe NPs utilize their distinct physicochemical properties to facilitate efficient nose-to-brain delivery, achieving high tumor accumulation while bypassing the BBB. The platform exhibits unique tumor-selective redox duality by generating cytotoxic reactive oxygen species and depleting glutathione within the tumors, yet activating antioxidant defense pathways in normal neural tissues to prevent neurotoxicity. This dual mechanism synergizes with AFA-induced tumor cell death. In orthotopic glioblastoma models, intranasal administration achieved a 60% long-term survival rate, driven by a chemoimmunotherapeutic response involving robust CD8+ T cell and macrophage infiltration. This study presents a multifunctional nanoplatform that integrates tumor microenvironment-responsive catalysis, non-invasive delivery, and immune reprogramming for precise and safe glioblastoma therapy.

PMID 42669245
Read full article →
PubMedFood chemistry: X2026-08-30

Ultrasound technology for edible mushrooms: A review of postharvest changes, applications and prospects.

Li Shaobin S, Wang Yutian Y, Fan Kai K

Edible mushrooms, as a dietary source rich in nutrients and diverse bioactive compounds, are widely appreciated by consumers worldwide. However, their high moisture content and delicate epidermis make them highly susceptible to quality deterioration, leading to a decline in both commercial and edible value. To extend the shelf lifeB66 of edible mushrooms, postharvest preservation is essential. Nevertheless, conventional preservation methods alone are insufficient to meet the demand for environmentally friendly and sustainable practices. This paper analyzes the physiological changes in edible mushrooms after harvest, and summarizes the improvements in quality and efficiency achieved through ultrasound-assisted traditional methods. Additionally, the regulatory effects of direct ultrasound treatment on microbial load and physiological activity in edible mushrooms are discussed. Although the commercial application of ultrasound technology currently faces challenges related to equipment optimization, it holds great promise as an important tool in the processing of edible mushrooms.

PMID 42668629
Read full article →
PubMedInternational journal of pharmaceutics2026-08-30

Polysaccharide-functionalized metal-polyphenol network-coated porous microspheres for improving the treatment of probiotics in ulcerative colitis.

Xiao Congcong C, Chen Bohan B, Gong Liming L, Feng Jing J et al.

Probiotic therapy offers a new approach to the treatment of ulcerative colitis (UC), but oral drug delivery still faces challenges such as low gastrointestinal survival rates, insufficient intestinal retention, and poor inflammatory targeting. In this study, a layer-by-layer encapsulation probiotic delivery system (HGM-L.re PM) was developed. Lactobacillus reuteri (L.re) was loaded onto poly-L-lactic acid porous microspheres, followed by in situ assembly of a tea polyphenol/Fe3+ metal-polyphenol network (MPN) coating, and then layer-by-layer electrostatic deposition of an ethylene glycol chitosan/ hyaluronate (GCS/HA) polysaccharide gel layers via electrostatic interactions. The porous microspheres provide efficient probiotic loading and physical protection; the MPN coating confers transferrin-responsive degradability, enabling on-demand release at sites of inflammation; the GCS/HA outer layer synergistically forms a dense gel network via acid-triggered electrostatic cross-linking to resist gastric erosion, while the terminal HA moiety specifically binds to CD44 to enhance colonic adhesion. Compared to unencapsulated probiotics, HGM-L.re PM demonstrated significantly enhanced viability protection throughout all simulated stages of gastrointestinal digestion and achieved retention for up to 72 h in mice with colitis. In a DSS-induced acute UC model, this formulation effectively alleviated weight loss and colonic shortening, reduced mucosal damage, downregulated IL-6, IL-1β, and TNF-α levels, upregulated IL-10, restored the expression of mucin and tight junction proteins, and reshaped the gut microbiota composition by enriching beneficial bacteria such as Lactobacillus species. The underlying mechanism involves metabolic reorientation and stress resolution. The formulation also demonstrated good in vivo safety. This layer-by-layer encapsulated probiotic delivery platform offers a new strategy for enhancing the efficacy of oral probiotic therapy for UC.

PMID 42669319
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about delivery technology